Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11104762 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Taniguchi T, et al. (2001) Phosphorylation of tau is regulated by PKN. J Biol Chem 276, 10025-31 11104762
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T181-p - tau iso8 (human) ▲
Orthologous residues
tau (human): T498‑p, tau iso2 (human): T123‑p, tau iso3 (human): T87‑p, tau iso5 (human): T181‑p, tau iso6 (human): T123‑p, tau iso8 (human): T181‑p, tau (mouse): T473‑p, tau iso3 (mouse): T170‑p, tau iso7 (mouse): T112‑p, tau (rat): T492‑p, tau (cow): T172‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  CHO (fibroblast), SK-N-MC (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKN1 (human) decrease activated

S202-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S519‑p, tau iso2 (human): S144‑p, tau iso3 (human): S108‑p, tau iso5 (human): S202‑p, tau iso6 (human): S144‑p, tau iso8 (human): S202‑p, tau (mouse): S494‑p, tau iso3 (mouse): S191‑p, tau iso7 (mouse): S151‑p, tau (rat): S513‑p, tau (cow): S209‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  CHO (fibroblast), SK-N-MC (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKN1 (human) decrease activated

T205-p - tau iso8 (human) ▲
Orthologous residues
tau (human): T522‑p, tau iso2 (human): T147‑p, tau iso3 (human): T111‑p, tau iso5 (human): T205‑p, tau iso6 (human): T147‑p, tau iso8 (human): T205‑p, tau (mouse): T497‑p, tau iso3 (mouse): T194‑p, tau iso7 (mouse): T154‑p, tau (rat): T516‑p, tau (cow): T212‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  CHO (fibroblast), SK-N-MC (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKN1 (human) decrease activated

S214-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S531‑p, tau iso2 (human): S156‑p, tau iso3 (human): S120‑p, tau iso5 (human): S214‑p, tau iso6 (human): S156‑p, tau iso8 (human): S214‑p, tau (mouse): S506‑p, tau iso3 (mouse): S203‑p, tau iso7 (mouse): S163‑p, tau (rat): S525‑p, tau (cow): S221‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKN1 (human)

T231-p - tau iso8 (human) ▲
Orthologous residues
tau (human): T548‑p, tau iso2 (human): T173‑p, tau iso3 (human): T137‑p, tau iso5 (human): T231‑p, tau iso6 (human): T173‑p, tau iso8 (human): T231‑p, tau (mouse): T523‑p, tau iso3 (mouse): T220‑p, tau iso7 (mouse): T180‑p, tau (rat): T542‑p, tau (cow): T238‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  CHO (fibroblast), SK-N-MC (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PKN1 (human) decrease activated

S258-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S575‑p, tau iso2 (human): S200‑p, tau iso3 (human): S164‑p, tau iso5 (human): S258‑p, tau iso6 (human): S200‑p, tau iso8 (human): S258‑p, tau (mouse): S550‑p, tau iso3 (mouse): S247‑p, tau iso7 (mouse): S207‑p, tau (rat): S569‑p, tau (cow): S265‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCB (human)
KINASE PKCI (human)
KINASE PKCE (human)
KINASE PKN1 (human)
KINASE PKCZ (human)
KINASE PKCB iso2 (human)
KINASE PKCA (human)
KINASE PKCG (human)

S293-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S610‑p, tau iso2 (human): ‑, tau iso3 (human): ‑, tau iso5 (human): ‑, tau iso6 (human): S235‑p, tau iso8 (human): S293‑p, tau (mouse): S585‑p, tau iso3 (mouse): S282‑p, tau iso7 (mouse): S242‑p, tau (rat): S604‑p, tau (cow): S300‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCE (human)
KINASE PKCB (human)
KINASE PKCZ (human)
KINASE PKCA (human)
KINASE PKCI (human)
KINASE PKCG (human)
KINASE PKCB iso2 (human)

S320-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S637‑p, tau iso2 (human): S231‑p, tau iso3 (human): S195‑p, tau iso5 (human): S289‑p, tau iso6 (human): S262‑p, tau iso8 (human): S320‑p, tau (mouse): S612‑p, tau iso3 (mouse): S309‑p, tau iso7 (mouse): S269‑p, tau (rat): S631‑p, tau (cow): S327‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  neuroblastoma
 Relevant cell lines - cell types - tissues:  CHO (fibroblast), SK-N-MC (neural crest)
 Cellular systems studied:  cell lines
 Species studied:  hamster, human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKN1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PKN1 (human) phospho-antibody, transfection of constitutively active enzyme
PHOSPHATASE PPP3CA (human) pharmacological inhibitor of upstream enzyme, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FK506 increase
vanadate increase
okadaic acid increase

S324-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S641‑p, tau iso2 (human): S235‑p, tau iso3 (human): S199‑p, tau iso5 (human): S293‑p, tau iso6 (human): S266‑p, tau iso8 (human): S324‑p, tau (mouse): S616‑p, tau iso3 (mouse): S313‑p, tau iso7 (mouse): S273‑p, tau (rat): S635‑p, tau (cow): S331‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCZ (human)
KINASE PKCG (human)
KINASE PKCE (human)
KINASE PKCB (human)
KINASE PKCA (human)
KINASE PKCB iso2 (human)
KINASE PKCI (human)

S352-p - tau iso8 (human) ▲
Orthologous residues
tau (human): S669‑p, tau iso2 (human): S263‑p, tau iso3 (human): S227‑p, tau iso5 (human): S321‑p, tau iso6 (human): S294‑p, tau iso8 (human): S352‑p, tau (mouse): S644‑p, tau iso3 (mouse): S341‑p, tau iso7 (mouse): S301‑p, tau (rat): S663‑p, tau (cow): S359‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE PKCI (human)
KINASE PKN1 (human)
KINASE PKCB (human)
KINASE PKCG (human)
KINASE PKCE (human)
KINASE PKCZ (human)
KINASE PKCA (human)
KINASE PKCB iso2 (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.